Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Neumora Therapeutics, Inc. | 80,000 | reported | 27 May 2026 | tx 29+542,179−327,494 |
| Jazz Pharmaceuticals plc | 58,948 | reported | 28 Nov 2008 | tx 7+89,130−19,879 |
| Crinetics Pharmaceuticals, Inc. | 38,836 | reported | 26 Sept 2025 | tx 46+285,850−164,400 |
| Atara Biotherapeutics, Inc. | 18,188 | reported | 10 Jun 2025 | tx 49+539,108−51,280 |
| Ultragenyx Pharmaceutical Inc. | 14,058 | reported | 14 May 2026 | tx 43+176,916−61,745 |
| MACROGENICS INC | 10,000 | reported | 16 May 2019 | tx 10+74,697−13,848 |
| ONYX PHARMACEUTICALS INC | 0 | reported | 01 Oct 2013 | tx 60+386,200−378,137 |
| Dermira, Inc. | 0 | reported | 20 Feb 2020 | tx 27+68,739−92,014 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 27 May 2026 | GRANT_AWARD | Neumora Therapeutics, Inc. | 80,000 | 0.00 USD | deriv |
| 14 May 2026 | GRANT_AWARD | Ultragenyx Pharmaceutical Inc. | 7,751 | 0.00 USD | |
| 14 May 2026 | GRANT_AWARD | Ultragenyx Pharmaceutical Inc. | 14,058 | 0.00 USD | deriv |
| 26 Sept 2025 | SALE | Crinetics Pharmaceuticals, Inc. | 16,000 | 44.75 USD | |
| 26 Sept 2025 | EXERCISE | Crinetics Pharmaceuticals, Inc. | 10,000 | 1.91 USD | |
| 26 Sept 2025 | EXERCISE | Crinetics Pharmaceuticals, Inc. | 10,000 | 0.00 USD | deriv |
| 11 Jun 2025 | GRANT_AWARD | Crinetics Pharmaceuticals, Inc. | 6,900 | 0.00 USD | |
| 11 Jun 2025 | GRANT_AWARD | Crinetics Pharmaceuticals, Inc. | 10,350 | 0.00 USD | deriv |
| 10 Jun 2025 | GRANT_AWARD | Atara Biotherapeutics, Inc. | 7,828 | 0.00 USD | |
| 28 May 2025 | GRANT_AWARD | Neumora Therapeutics, Inc. | 27,802 | — | deriv |
| 28 May 2025 | OTHER | Neumora Therapeutics, Inc. | 85,586 | — | deriv |
| 28 May 2025 | OTHER | Neumora Therapeutics, Inc. | 27,802 | — | deriv |
| 28 May 2025 | GRANT_AWARD | Neumora Therapeutics, Inc. | 28,571 | — | deriv |
| 28 May 2025 | GRANT_AWARD | Neumora Therapeutics, Inc. | 80,000 | 0.00 USD | deriv |
| 28 May 2025 | OTHER | Neumora Therapeutics, Inc. | 28,571 | — | deriv |
| 28 May 2025 | GRANT_AWARD | Neumora Therapeutics, Inc. | 85,586 | — | deriv |
| 15 May 2025 | GRANT_AWARD | Ultragenyx Pharmaceutical Inc. | 5,740 | 0.00 USD | |
| 15 May 2025 | GRANT_AWARD | Ultragenyx Pharmaceutical Inc. | 10,787 | 0.00 USD | deriv |
| 13 Feb 2025 | GRANT_AWARD | Neumora Therapeutics, Inc. | 28,571 | — | deriv |
| 13 Feb 2025 | OTHER | Neumora Therapeutics, Inc. | 85,586 | — | deriv |
| 13 Feb 2025 | OTHER | Neumora Therapeutics, Inc. | 27,802 | — | deriv |
| 13 Feb 2025 | OTHER | Neumora Therapeutics, Inc. | 28,571 | — | deriv |
| 13 Feb 2025 | GRANT_AWARD | Neumora Therapeutics, Inc. | 85,586 | — | deriv |
| 13 Feb 2025 | GRANT_AWARD | Neumora Therapeutics, Inc. | 27,802 | — | deriv |
| 18 Oct 2024 | EXERCISE | Neumora Therapeutics, Inc. | 6,205 | 8.79 USD |